Endothelial Haemostatic Factors May Be Associated with Mortality in Patients on Long-term Anticoagulant Treatment

Summary

The aim of the present study was to test if long-term mortality could be predicted by endothelial derived haemostatic variables in a population with high morbidity due to thromboembolic disease. Plasma samples were drawn from 212 out-patients treated with oral anticoagulants, at the beginning of the study, and analyzed for mass concentration of tissue plasminogen activator (tPA) and its inhibitor (PAI-1), and von Willebrand factor. In the course of 3.8-year follow-up 45 patients died, including 38 vascular deaths. We found that all-cause mortality was significantly associated with increased levels of vWF and tPA. For vascular mortality there was a significant association with all three haemostatic variables (tPA, PAI-1, vWF). For vWF there was a 3-fold increase in total and vascular mortality in the highest quartile compared to the lowest quartile. There were 27 vascular deaths in the group of patients with a tPA-value above the median compared to 11 in those with a tPA below the median. In multivariate Cox regression analysis (including: age, sex, smoking habits, body mass index, diabetes mellitus, hypertension, tPA, PAI-1, and vWF), vWF and smoking were independently significantly associated with all-cause mortality, and tPA and age with vascular mortality. Endothelial derived haemostatic variables are predictors of total and vascular mortality in patients treated with oral anticoagulants.

• References

• 1 Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
• 2 Jansson JH, Nilsson TK, Ololsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161
• 3 Thompson SG for the European Concerted Action on Thrombosis and disabilities (LCAT). Hot line results. XIVth Congress of the European Society of Cardiology Barcelona; Spain: 1992. 08 30- 09 03
• 4 Corlellaro M, Cofrancesco E, Bosehetti C. et al. for the PLAT Group. Increased fibrin turnover and high PAI-I activity as predictors of ischemic events in atherosclerotic patients Arteriosclerosis and Thrombosis 1993; 13: 1412-1417
• 5 Ridker PM, Vaughan DE, Slampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168
• 6 Korninger C, Lechner K, Niessner H, Gæssinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127-130
• 7 Haines AP, Howarth D, North WR S. el al Haemostatic variables and the outcome of myocardial infarction. Thromb Haemost 1983; 50: 800-803
• 8 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. British Heart Journal 1991; 66: 351-355
• 9 Corlellaro M, Bosehetti C, Cofrancesco E. et al The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results Arteriosclerosis and Thrombosis 1992; 12: 1063-1070
• 10 Nilsson TK, Jansson J-H. Haemostatic variables of the endothelial cells as predictors. XIVth Congress of the International Societyon Thrombosis and Haemostasis. New York, USA: 1993. Abstract number T04-0020
• 11 Brännström Mats, Boman Kurt, Jansson Jan-Håkan, Nilsson Törbjorn. Haemostatic variables can predict mortality in patients on oral anticoagulants. XVth Congress of the European Society of Cardiology, Nice, France, 1993 European Heart Journal 1993; 14 (Abstract Supplement) Abstract No P 1269
• 12 RÅnby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-2165
• 13 Cejka J. Enzyme immunoassay for factor VUI-related antigen. Clin Chem 1982; 28: 1356-1358
• 14 Ray AA. SAS User’s Guide: Basics. Cary, NC: SAS Institute; 1986
• 15 Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; 34: 187-220
• 16 Ogston D. The Physiology of Haemostasis. Croom Helm; London: 1983
• 17 Sundell B, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42: 719-723
• 18 Delivery statistics of the National Corporation of Swedish Farmacies. 1990
• 19 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152
• 20 Petersen P, Boy sen G, Godtfredsen J, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989; 1: 175-179
• 21 Special Report: preliminary report of the Stroke Prevention in Atrial Fibrillation study. N Engl J Med 1990; 322: 863-868
• 22 Petersen P, Kastrup J, Helweg-Larsen S, Boysen G, Godtfredsen J. Risk- factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Arch Intern Med 1990; 150: 819-921